Search This Blog

Thursday, March 26, 2026

Novocure's Phase 2 PANOVA-4 in first-line metastatic pancreatic cancer meets primary endpoint

 

Novocure's Phase 2 PANOVA-4 in first-line metastatic pancreatic cancer meets primary endpoint with Tumor Treating Fields plus atezolizumab and chemotherapy

  • Combination therapy achieved a significantly higher disease control rate versus historical control in PANOVA-4 first-line patients.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)